GADOTERATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Gadoterate, and what generic alternatives are available?
Gadoterate is a drug marketed by Hainan Poly and Hengrui Pharma and is included in two NDAs.
The generic ingredient in GADOTERATE is gadoterate meglumine. Four suppliers are listed for this compound. Additional details are available on the gadoterate meglumine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Gadoterate
A generic version of GADOTERATE was approved as gadoterate meglumine by HAINAN POLY on June 17th, 2024.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for GADOTERATE?
- What are the global sales for GADOTERATE?
- What is Average Wholesale Price for GADOTERATE?
Summary for GADOTERATE
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| DailyMed Link: | GADOTERATE at DailyMed |
US Patents and Regulatory Information for GADOTERATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hainan Poly | GADOTERATE MEGLUMINE | gadoterate meglumine | SOLUTION;INTRAVENOUS | 218073-001 | Jun 17, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Hengrui Pharma | GADOTERATE MEGLUMINE | gadoterate meglumine | SOLUTION;INTRAVENOUS | 215304-002 | Apr 11, 2022 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Hainan Poly | GADOTERATE MEGLUMINE | gadoterate meglumine | SOLUTION;INTRAVENOUS | 218073-004 | Jun 17, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
